Table II.
Clinical analysis of nuclear factor erythroid 2-related factor 2 expression in diffuse large B-cell lymphoma.
| Clinical characteristic | Nuclear Nrf2-positive | Nuclear Nrf2-negative | P-value |
|---|---|---|---|
| Subtype | 0.0196a | ||
| ABC | 10 | 20 | |
| GCB | 0 | 13 | |
| HBsAg | 0.0487a | ||
| Positive | 4 | 4 | |
| Negative | 4 | 25 | |
| N.D. | 2 | 4 | |
| BWL | 0.0421a | ||
| Yes | 6 | 9 | |
| No | 2 | 20 | |
| N.D. | 2 | 4 | |
| WBC, µl | 6471.3±1290.6 | 7500.0±4220.8 | 0.5043 |
| Platelet, ×103/µl | 201.1±83.8 | 239.8±136.6 | 0.3207 |
| GOT, U/l | 37.1±29.5 | 36.0±31.5 | 0.9621 |
| GPT, U/l | 35.4±38.0 | 25.9±17.1 | 0.3044 |
| Ionized calcium, mg/dl | 5.1±0.4 | 4.7±0.4 | 0.0134a |
Data are presented as n or mean ± standard deviation.
a
P<0.05. Nrf2, nuclear factor erythroid 2-related factor 2; ABC, activated B-cell; GCB, germinal center B-cell; HBsAg, hepatitis B surface antigen; BWL, body weight loss; WBC, white blood cell; GOT, glutamate oxaloacetate transaminase; GPT, glutamate pyruvate transaminase; N.D., not detected.